Tıp Fakültesi / Faculty of Medicine

Permanent URI for this collectionhttps://hdl.handle.net/11727/1403

Browse

Filters

2015 - 20162

Settings

Author: search.filters.author.Koktekir, Bengu EkinciSubject: search.filters.subject.Migraine

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Evaluation of Choroidal Thickness Using Spectral-Domain Optical Coherence Tomography in Patients with Migraine: A Comparative Study
    (2015) Karalezli, Aylin; Celik, Guner; Koktekir, Bengu Ekinci; Kucukerdonmez, Cem; 25633615; GOE-6067-2022; HTO-3612-2023
    Purpose: To assess choroidal thickness in patients with migraine and compare them with healthy controls, using spectral-domain optical coherence tomography (OCT). Methods: In this prospective case-control study, choroidal thicknesses of 20 newly diagnosed migraine patients and 20 age-and sex-matched healthy subjects were measured using a high-speed, high-resolution frequency domain (FD) OCT device (lambda = 840 nm, 26.000 A-scans/s, 5 mu m axial resolution). All patients underwent a complete ophthalmic examination before the measurements. OCT measurements were taken at the same time of day (9: 00 AM), in order to minimize the effects of diurnal variation. Results: There was a statistically significant difference in median choroidal thickness between the migraine patients (277.00 [interquartile range (IQR) 85.75] mu m) and controls (301.00 [IQR 90.50] mu m) (p = 0.012). There were significant differences at all measurement points (p<0.05 for all). Conclusions: The decreased choroidal thickness of patients with migraine might be related to the vascular pathology of the disease. Further studies are needed to evaluate the etiopathologic relationship between choroidal thickness and migraine.
  • No Thumbnail Available
    Item
    Topiramate-Induced Changes in Anterior Chamber Angle and Choroidal Thickness
    (2016) Karalezli, Aylin; Koktekir, Bengu Ekinci; Celik, Guner; 26020486; GOE-6067-2022
    Purpose: To investigate the acute effects of topiramate on the anterior chamber angle (ACA) and choroidal thickness in patients with migraine. Methods: This prospective study included 15 eyes of 15 patients with migraine who have been scheduled to start topiramate therapy. All patients underwent complete ophthalmic examination including measurement of the ACA and choroidal thickness using a spectral domain optical coherence tomography device (Optovue Inc.) and refractive status evaluation with an autorefractokeratometer (KR-8100; Topcon) at the baseline and 1 week after starting therapy. The patients were asked to report any pain or discomfort in their eyes during therapy at the follow-up visit. Results: None of the patients experienced pain or discomfort in their eyes. The mean ACA significantly decreased at the first week of the therapy compared with the baseline levels (40.34 +/- 7.06 degrees and 36.89 +/- 6.87 degrees, respectively) (P=0.001). However, the mean choroidal thickness increased from 277.33 +/- 95.60 mu m at the baseline to 323.40 +/- 84.50 mu m at the first week (P=0.01). There was a nonsignificant increase in the mean refractive error (from -0.25 +/- 0.54 diopter [D] at the baseline to -0.38 +/- 0.49 D after 1 week) (P=0.06). Conclusions: Topiramate can acutely decrease the ACA and increase the choroidal thickness. Because these effects may be asymptomatic, patients with migraine who start this therapy should be warned to be closely followed up by an ophthalmologist.